Retinoblastoma Binding Proteins
"Retinoblastoma Binding Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of endogenous regulatory proteins that associate with RETINOBLASTOMA PROTEIN via a specific high-affinity binding domain. Members of this family of proteins are often found associated with histone-modifying enzymes and protein complexes that regulate gene expression.
| Descriptor ID |
D056286
|
| MeSH Number(s) |
D12.644.360.024.328 D12.776.157.057.158 D12.776.476.024.420 D12.776.660.769
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Retinoblastoma Binding Proteins".
Below are MeSH descriptors whose meaning is more specific than "Retinoblastoma Binding Proteins".
This graph shows the total number of publications written about "Retinoblastoma Binding Proteins" by people in this website by year, and whether "Retinoblastoma Binding Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 3 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Retinoblastoma Binding Proteins" by people in Profiles.
-
Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies. Clin Cancer Res. 2024 Oct 15; 30(20):4768-4779.
-
MULTIPLYING BROWN SPOTS. Retin Cases Brief Rep. 2024 Sep 01; 18(5):642-646.
-
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
-
Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma. HGG Adv. 2023 10 12; 4(4):100224.
-
RB1 alteration and poor prognosis in women with high-grade neuroendocrine carcinoma of the uterine cervix: a NeCTuR study. J Gynecol Oncol. 2023 07; 34(4):e50.
-
Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proc Natl Acad Sci U S A. 2022 04 19; 119(16):e2117857119.
-
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574.
-
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. Cancer. 2021 08 01; 127(15):2666-2673.
-
Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis. Mod Pathol. 2020 07; 33(7):1256-1263.
-
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6839-6851.